September 5, 2023 |
This whitepaper will explore multidisciplinary perspectives on how we can better engage patient communities in publications to optimize the value of their contributions, while navigating any uncertainties and reluctance from internal and external stakeholders.
The biopharmaceutical sector continues to recognize the value of integrating the voice of the patient community into its activities.
Despite growing recognition of the importance of patient partnership within publications, uncertainty remains regarding how best to involve patients and where in the process this involvement should happen. Furthermore, although many of our colleagues working in Medical Affairs and publications have established the goal of engaging patients in publications, possibly as authors, their own internal guidance on publication development may create roadblocks. Compliance and regulatory concerns can limit opportunities to partner with patient communities, and the occasional reluctance of physician authors to include patients as co-authors further exacerbates the situation. Additional barriers arise from the general uncertainty in the scientific communications community as to how and when to engage patients in an appropriate manner that ensures a positive experience and recognizes the resource challenges of advocacy groups.
This paper will explore multidisciplinary perspectives on how we can better engage patient communities in publications to optimize the value of their contributions, while navigating any uncertainties and reluctance from internal and external stakeholders. We recognize that we are all learning together, with the shared goal of evolving our practices to fully embrace the voice of the patient while adhering to publication best practices and compliance. We welcome and encourage feedback from our industry colleagues to further refine our approaches.
This article was originally published in our latest whitepaper “Embracing the Patient Voice Within Publications”. To learn more about the multidisciplinary perspectives on how to better engage patient communities in publications, read the full whitepaper.
This content was provided by OPEN Health
Company Details
Latest Content from OPEN Health
To mark Rare Disease Day 2021 on Sunday 28 February, OPEN Health will be intentionally quiet on all LinkedIn channels from 26 February to 1 March in order not to…
If the heart of the medical affairs industry is ultimately improving patient outcomes, internal training is the regenerative liver. Med affairs professionals need to regularly update their scientific knowledge and…
How fantastic is it to see that the National Organisation for Rare Disorders (NORD) has followed up on a survey undertaken in the late 80’s to pressure test progress and identify…
OPEN Health Group today announced that Rob Barker has been appointed Chief Executive Officer. Rob succeeds outgoing CEO and Co-Founder, David Rowley, who is stepping down after 10 years. A…
Join OPEN VIE and Pharmerit – an OPEN Health Company at the ISPOR European Virtual Conference from 16-19 November 2020 to see how we are shaping the healthcare industry with…
Strategy and execution, data and insight, experience and innovation…what do you look for in an agency partner?OPEN Health is a family of expert practices working in partnership to drive positive…
The COVID-19 pandemic has permanently changed how medical education in the healthcare industry is conducted. Over the last few months, all conferences, medical education and field force deliverables have either…
Join OPEN Health’s virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…
Gavin Jones, Director of Rare Disease, provides his thoughts on last week’s NORD Breakthrough Summit and a collective need to reduce inequalities in rare disease
Hear from OPEN Health’s Briony Frost
